Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood Tests Offer Early Indicator of Severe COVID-19

By LabMedica International staff writers
Posted on 09 Mar 2021
For most patients, COVID-19 manifests as an upper respiratory tract infection that is self-limited. More...
However, the progression of COVID-19 in a large subset of patients to respiratory distress, multiorgan failure, and death has resulted in an enormous global impact.

Previously, a few laboratory studies had identified possible indicators of severe COVID-19, including D-dimer levels, a measure of blood coagulation, and levels of proteins known as cytokines, which are released as part of inflammatory responses in the body.

A multidisciplinary team of medical scientists at Yale School of Medicine (New Haven, CT, USA) conducted a study of 49 adult patients admitted to Yale-New Haven Hospital between 13 and 24 April, 2020 with a confirmed diagnosis of COVID-19 via polymerase chain reaction (cross-sectional cohort). The team also analyzed blood samples obtained longitudinally on days 1 (within 24 hours), 4, and 7 of hospitalization from a separate cohort of 23 consecutive adult patients admitted for treatment of laboratory-confirmed COVID-19 between 23 and 28 May 2020 who remained hospitalized until at least day 4 (longitudinal cohort).

Biomarker profiling analyses were conducted at Eve Technologies (Calgary, AB, Canada). For the cross-sectional cohort, the following assays were performed: Human Cytokine 71-Plex, Human Complement Panels 1 and 2, Human SAA & ADAMTS13, and Human Adipokine 5-Plex. For the longitudinal cohort, the following assays were performed: Human Cytokine 48-Plex, Human Complement Panel 1, Human Adipokine 5-Plex, and Human MMP 9-Plex and TIMP 4-Plex. For confirmation, RETN levels were also measured by enzyme-linked immunosorbent assay (ELISA) (R&D Systems, Minneapolis, MN, USA).

The scientists identified a prominent signature of neutrophil activation, including resistin, lipocalin-2, hepatocyte growth factor, interleukin-8, and granulocyte colony-stimulating factor, which were the strongest predictors of critical illness. Evidence of neutrophil activation was present on the first day of hospitalization in patients who would only later require transfer to the intensive care unit, thus preceding the onset of critical illness and predicting increased mortality. All COVID-19 patients who were admitted or transferred to the ICU had elevated neutrophil activation markers, while these biomarkers remained low for patients who never developed severe illness. None of the patients with lower neutrophil biomarker levels died.

Hyung J. Chun, MD, FAHA, an associate professor of medicine and lead author of the study, said, “If a diagnostic test for these biomarkers could be ordered early, it could give us a better sense of who is more likely to become critically ill and will benefit from a higher level of care and consideration for therapies that affect the immune system early on in their hospitalization. Many of these drugs do carry potential side effects, and these tests may help identify those patients who would benefit the most.”

The authors concluded that their study highlights a central role for neutrophil activation in the pathogenesis of severe COVID-19, which may help guide the development of new therapeutic strategies and more accurate predictive markers of severe disease. The study was published on February 26, 2021 in the journal Blood Advances.

Related Links:
Yale School of Medicine
Eve Technologies
R&D Systems



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis

Lung cancer is a leading cause of cancer-related death worldwide and is characterized by substantial cellular heterogeneity. Even within a single tumor, cancer cells can vary in aggressiveness, while immune,... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.